Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

Moderna MRNA announced positive results from an ongoing late-stage study evaluating mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID-19, in older adults (50 years and older). The phase III study met its primary endpoints, showing that mRNA-1083 elicited higher immune responses against influenza and COVID-19 compared with licensed standalone influenza and COVID-19 vaccines. These results are based on a study that evaluated the vaccine in about 8,000 adults divided into two independent age group cohorts. The first cohort, …